1-((R)-3-氨基-吡咯烷-1-基)-乙酮 | 1000870-09-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-((R)-3-氨基-吡咯烷-1-基)-乙酮
• 中文别名: R-1-乙酰基-3-氨基吡咯烷盐酸盐
• 英文名称: (R)-1-acetyl-3-aminopyrrolidine
• 英文别名: (R)-1-(3-aminopyrrolidin-1-yl)ethanone；1-[(3R)-3-aminopyrrolidin-1-yl]ethanone；1-((R)-3-Amino-pyrrolidin-1-yl)-ethanone
• CAS: 1000870-09-6
• 化学式: C₆H₁₂N₂O
• 分子量: 128.174
• InChiKey: QTFVAHXVSVHNQR-ZCFIWIBFSA-N

物化性质

• 沸点：
  256.9±33.0 °C(Predicted)
• 密度：
  1.080±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-((R)-3-氨基-吡咯烷-1-基)-乙酮 、 6-氯嘌呤核苷 在 ammonium hydroxide 作用下， 以 叔丁醇 为溶剂， 反应 26.0h， 以66.5%的产率得到N⁶-((R)-1-acetylpyrrolidin-3-yl)adenosine
  参考文献：
  名称：

  Structure–activity relationships of adenosines with heterocyclic N6-substituents

  摘要：

  Two series of N-6-substituted adenosines with monocyclic and bicyclic N-6 substituents containing a heteroatom were synthesized in good yields. These derivatives were assessed for their affinity ([H-3]CPX), potency, and intrinsic activity (cAMP accumulation) at the A, adenosine receptor in DDT1 MF-2 cells. In the monocyclic series, the N-6-tetrahydrofuran-3-yl and thiolan-3-yl adenosines (1 and 26, respectively) were found to possess similar activities, whereas the corresponding selenium analogue 27 was found to be more potent. A series of nitrogen containing analogues showed varying properties, N-6-((3R)-1-benzyloxycarbonylpyrrolidin-3-yl)adenosine (30) was the most potent at the AIAR; IC50 = 3.2 nM. In the bicyclic series, the effect of a 7-azabicyclo[2.2.1]heptan-2-yl substituent in the N-6-position was explored. N6- (7-Azabicyclo[2.2.1] heptan-2-yl)adeno sine (38) proved to be a reasonably potent A, agonist (K-i = 51 nM, IC50 = 35 nM) while further substitution on the 7 ''-nitrogen with tert-butoxycarbonyl (31, IC50 = 2.5 nM) and 2-bromobenzyloxycarbonyl (34, IC50 = 9.0 nM) gave highly potent A(1)AR agonists. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.028
• 作为产物：
  描述：

  乙酸酐 、 (R)-3-氨基吡咯烷 在 盐酸 作用下， 以 甲醇 为溶剂， 反应 2.0h， 以97.3%的产率得到1-((R)-3-氨基-吡咯烷-1-基)-乙酮
  参考文献：
  名称：

  Structure–activity relationships of adenosines with heterocyclic N6-substituents

  摘要：

  Two series of N-6-substituted adenosines with monocyclic and bicyclic N-6 substituents containing a heteroatom were synthesized in good yields. These derivatives were assessed for their affinity ([H-3]CPX), potency, and intrinsic activity (cAMP accumulation) at the A, adenosine receptor in DDT1 MF-2 cells. In the monocyclic series, the N-6-tetrahydrofuran-3-yl and thiolan-3-yl adenosines (1 and 26, respectively) were found to possess similar activities, whereas the corresponding selenium analogue 27 was found to be more potent. A series of nitrogen containing analogues showed varying properties, N-6-((3R)-1-benzyloxycarbonylpyrrolidin-3-yl)adenosine (30) was the most potent at the AIAR; IC50 = 3.2 nM. In the bicyclic series, the effect of a 7-azabicyclo[2.2.1]heptan-2-yl substituent in the N-6-position was explored. N6- (7-Azabicyclo[2.2.1] heptan-2-yl)adeno sine (38) proved to be a reasonably potent A, agonist (K-i = 51 nM, IC50 = 35 nM) while further substitution on the 7 ''-nitrogen with tert-butoxycarbonyl (31, IC50 = 2.5 nM) and 2-bromobenzyloxycarbonyl (34, IC50 = 9.0 nM) gave highly potent A(1)AR agonists. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.10.028

文献信息

• QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS
  申请人：Wilson Dean

  公开号：US20080167305A1

  公开（公告）日：2008-07-10

  The present invention relates to compounds useful as inhibitors of voltage-gated sodium channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及作为电压门控钠通道抑制剂有用的化合物。该发明还提供了包括本发明化合物的药学上可接受的组合物，以及使用这些组合物治疗各种疾病的方法。
• APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
  申请人：Bruncko Milan

  公开号：US20100305122A1

  公开（公告）日：2010-12-02

  Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

  揭示了抑制抗凋亡Bcl-2蛋白活性的化合物，含有这些化合物的组合物以及治疗在其中表达抗凋亡Bcl-2蛋白的疾病的方法。
• [EN] BENZODIOXANE INHIBITORS OF LEUKOTRIENE PRODUCTION<br/>[FR] INHIBITEURS BENZODIOXANES DE PRODUCTION DE LEUCOTRIÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2012125598A1

  公开（公告）日：2012-09-20

  The present invention relates to compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein. The compounds of formula (I) are useful as inhibitors of leukotriene A4 hydrolase (LTA4H) and treating LTA4H related disorder. The present invention also relates to pharmaceutical compositions comprising the compounds of formula (I), methods of using these compounds in the treatment of various diseases and disorders, and processes for preparing these compounds.

  本发明涉及式(I)的化合物：其中R1至R3、A、X和n如本文所定义。式(I)的化合物可用作白三烯A4水解酶(LTA4H)的抑制剂，并用于治疗与LTA4H相关的疾病。本发明还涉及包含式(I)化合物的药物组合物，使用这些化合物治疗各种疾病和疾病的方法，以及制备这些化合物的方法。
• Adamantyl Iminocarbonyl-Substituted Pyrimidines As Inhibitors Of 11-Beta-HSD1 826
  申请人：Bennett Stuart Norman Lile

  公开号：US20110092526A1

  公开（公告）日：2011-04-21

  A compound of formula (I): and pharmaceutically-acceptable salts thereof, wherein the variable groups are defined within; their use in the inhibition of 11βHSD1, processes for making them and pharmaceutical compositions comprising them are also described herein.

  公式(I)的化合物：以及药理可接受的盐，其中变量组在内部定义；它们用于抑制11βHSD1，制造它们的过程以及包含它们的药物组合物也在本文中描述。
• [EN] FLUORINATED LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS FLUORÉS DE LA LYSYL OXYDASE-LIKE 2 ET UTILISATIONS DESDITS INHIBITEURS
  申请人：PHARMAKEA INC

  公开号：WO2016144703A1

  公开（公告）日：2016-09-15

  Described herein are compounds that are LOXL2 inhibitors, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.

  本文描述的是一种LOXL2抑制剂化合物，制备这种化合物的方法，包含这种化合物的药物组合物和药物，以及使用这种化合物治疗与LOXL2活性相关的疾病、病症或疾病的方法。